199 related articles for article (PubMed ID: 34427448)
21. Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor.
Suleman M; Yousafi Q; Ali J; Ali SS; Hussain Z; Ali S; Waseem M; Iqbal A; Ahmad S; Khan A; Wang Y; Wei DQ
Comput Biol Med; 2021 Nov; 138():104936. PubMed ID: 34655895
[TBL] [Abstract][Full Text] [Related]
22. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
23. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Clausen TM; Sandoval DR; Spliid CB; Pihl J; Perrett HR; Painter CD; Narayanan A; Majowicz SA; Kwong EM; McVicar RN; Thacker BE; Glass CA; Yang Z; Torres JL; Golden GJ; Bartels PL; Porell RN; Garretson AF; Laubach L; Feldman J; Yin X; Pu Y; Hauser BM; Caradonna TM; Kellman BP; Martino C; Gordts PLSM; Chanda SK; Schmidt AG; Godula K; Leibel SL; Jose J; Corbett KD; Ward AB; Carlin AF; Esko JD
Cell; 2020 Nov; 183(4):1043-1057.e15. PubMed ID: 32970989
[TBL] [Abstract][Full Text] [Related]
25. COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans.
Frutos R; Serra-Cobo J; Chen T; Devaux CA
Infect Genet Evol; 2020 Oct; 84():104493. PubMed ID: 32768565
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
Baig MS; Alagumuthu M; Rajpoot S; Saqib U
Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
[TBL] [Abstract][Full Text] [Related]
27. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
28. Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes.
Hadi-Alijanvand H; Rouhani M
J Proteome Res; 2020 Nov; 19(11):4609-4623. PubMed ID: 32786692
[TBL] [Abstract][Full Text] [Related]
29. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
30. Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence.
Laurini E; Marson D; Aulic S; Fermeglia A; Pricl S
ACS Nano; 2021 Apr; 15(4):6929-6948. PubMed ID: 33733740
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
32. Structural and functional modelling of SARS-CoV-2 entry in animal models.
Brooke GN; Prischi F
Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513
[TBL] [Abstract][Full Text] [Related]
33. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
34. In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding.
Bate N; Savva CG; Moody PCE; Brown EA; Evans SE; Ball JK; Schwabe JWR; Sale JE; Brindle NPJ
PLoS Pathog; 2022 Jul; 18(7):e1010733. PubMed ID: 35849637
[TBL] [Abstract][Full Text] [Related]
35. Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein.
Heinzelman P; Romero PA
PLoS One; 2021; 16(5):e0251585. PubMed ID: 33979391
[TBL] [Abstract][Full Text] [Related]
36. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
[TBL] [Abstract][Full Text] [Related]
37. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes.
Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL
J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095
[TBL] [Abstract][Full Text] [Related]
38. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
[TBL] [Abstract][Full Text] [Related]
39. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
40. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
